nimodipine has been researched along with Peripheral Nerve Injuries in 2 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Peripheral Nerve Injuries: Injuries to the PERIPHERAL NERVES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nimodipine treatment also increased the number of myelinated fibers while decreasing their thickness, as shown by histomorphometry." | 1.91 | Enhancement of nerve regeneration with nimodipine treatment after sciatic nerve injury. ( Abdolmaleki, A; Al-Saedi, HF; Asadi, A; Ghanimi, HA; Panahi, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Saedi, HF | 1 |
| Panahi, Y | 1 |
| Ghanimi, HA | 1 |
| Abdolmaleki, A | 1 |
| Asadi, A | 1 |
| Odorico, SK | 1 |
| Shulzhenko, NO | 1 |
| Zeng, W | 1 |
| Dingle, AM | 1 |
| Francis, DO | 1 |
| Poore, SO | 1 |
2 other studies available for nimodipine and Peripheral Nerve Injuries
| Article | Year |
|---|---|
Enhancement of nerve regeneration with nimodipine treatment after sciatic nerve injury.
Topics: Animals; Male; Nerve Regeneration; Nimodipine; Peripheral Nerve Injuries; Rats; Rats, Wistar; Recove | 2023 |
Effect of Nimodipine and Botulinum Toxin A on Peripheral Nerve Regeneration in Rats: A Pilot Study.
Topics: Animals; Botulinum Toxins, Type A; Combined Modality Therapy; Disease Models, Animal; Humans; Male; | 2021 |